category,datetime,headline,id,image,related,source,summary,url
company,1768916100,BrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and Innovation,138186547,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"BrightInsight Expands Executive Leadership Team with Key Hires BrightInsight appoints three industry veterans to its Executive Leadership Team (ELT). Joining the company are Robert Zdon as Chief Operating Officer, Eric Redline as Senior Vice President of Market Development and Customer Success, and Leigh Wager as Vice President of Product. SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc., the leading global platform for biopharma digital health solutions, today announced t",https://finnhub.io/api/news?id=35ea8f4540f4384f5720ee6ff498cb0e33f8d8b424e1a03b096753d4fdd3b616
company,1768915800,BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions,138186548,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight, a leader in digital health solutions, today announced a new investment round of $13 million from existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight’s AI-enabled medication persistence and adherence solutions and enable rapid scalability of high-impact programs, such as the Patient App from its c",https://finnhub.io/api/news?id=733cc7b0bc11522695c9c904253e5bf989f63580522b3a4028404e350e406c76
company,1768915735,Should You Be Excited for Regeneron (REGN)?,138186549,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund returned 3.35% in the quarter, compared to the S&P 500’s 2.66% and the Russell 1000 Value Index’s 3.81% return. 2025 was a challenging year for the firm, as it did not have any […]",https://finnhub.io/api/news?id=4dac52c11cb3f601476f133e5076946664904ff3f2490335fb2f8c70ffa1727b
company,1768907244,A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum,138185750,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"Triggered look at Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals (REGN) has recently drawn attention after a period where the share price showed mixed short term returns but a stronger move over the past 3 months, prompting a closer look at its fundamentals. See our latest analysis for Regeneron Pharmaceuticals. At a share price of US$733.04, Regeneron has seen a 25.36% 90 day share price return, while the 1 year total shareholder return of 7.17% and 5 year total shareholder...",https://finnhub.io/api/news?id=e16c7d49c5f7fa1e15eb5852cc636893d7581c914a5dfffc3126988b6417ca61
